DKSH and Pharmanovia Partner to Respond to Therapeutic Needs in Southeast Asia

DKSH will support Lifecycle management firm Pharmanovia in its mission to bring important medication to patients across Southeast Asia. 

London, UK / Bangkok, TH - 11 July, 2022 – DKSH, a leading partner for healthcare companies seeking to grow their business in Asia and beyond, has partnered with life cycle management company Pharmanovia, to bring high-quality pharmaceutical products to patients across the Asia Pacific. 

Partnering in Laos, Cambodia, Myanmar, Hong Kong, Singapore, Taiwan, Malaysia, and the Philippines, the two companies seek to solidify brand presence, grow market share, and ultimately improve patient health outcomes in Southeast Asia.

DKSH will support Pharmanovia by building dedicated sales and marketing teams on the ground in Asia and manage product distribution in the markets. The firm’s experienced teams and broad distribution network will ensure Pharmanovia’s products reach modern trade, traditional trade, hospitals, clinics, other medical channels, and patients in need across the region.

Pharmanovia’s mission is to progress iconic medicines for the benefit of patient health. As brand owners of some of the world’s most recognizable brands, Pharmanovia’s aim is not only to revitalize the sales and marketing of iconic brands and pharmaceutical products but also to re-engineer the products and develop new delivery systems, answering the therapeutic needs of both doctors and patients. 

Dimitri Pimbert, General Manager APAC, Pharmanovia, commented: “We are delighted to be partnering with DKSH as part of our ongoing international expansion and our mission to increase access to drugs across the world. The breadth of medicines available in Southeast Asia is increasing, but more attention and resources need to be dedicated to revitalizing existing medicines and ensuring they are accessible to all within the region. We are confident in DKSH's ability to support us in this goal. Their strong regional footprint in Asia, as well as their marketing and sales expertise should help to further strengthen Pharmanovia’s brands and its continued growth.”

Bijay Singh, Head of Business Unit Healthcare at DKSH, added: “We are excited to enter this partnership with Pharmanovia, whose outstanding product strategy is deeply aligned with our mission of providing healthcare for all and answering the therapeutic needs of doctors and patients.”

About DKSH 

DKSH’s purpose is to enrich people’s lives. For more than 150 years, we have been delivering growth for companies in Asia and beyond across our Business Units Healthcare, Consumer Goods, Performance Materials, and Technology. As a leading Market Expansion Services provider, we offer sourcing, market insights, marketing and sales, eCommerce, distribution and logistics as well as after-sales services. DKSH is a participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business. Listed on the SIX Swiss Exchange, DKSH operates in 36 markets with 33,100 specialists, generating net sales of CHF 11.1 billion in 2021. The DKSH Business Unit Healthcare distributes pharmaceuticals, consumer health and over-the-counter (OTC) products as well as medical devices. With around 7,290 specialists, the Business Unit generated net sales of CHF 5.6 billion in 2021. www.dksh.com/hec 

About Pharmanovia

Pharmanovia is a dynamic, fast growing international pharmaceutical company with a portfolio of over 20 brands across more than 140 markets. Our mission is to improve patient health globally through the revitalisation of niche, tried and trusted medicines. Since its inception in 2013, Pharmanovia has grown consistently year on year, focusing on delivering high quality branded prescription medicines to patients, prescribers and healthcare providers across the world. Our growth has enabled the company to reinvest in its products, brands, people, and to give back to its communities. A people business with a strong, supportive culture that encourages innovation and entrepreneurial spirit, our team comprises over 250 employees and 29 nationalities, operating from offices in the UK, Denmark, Netherlands, Switzerland, U.A.E., India, Singapore, Italy and South Korea.

We are an agile and imaginative global specialty pharma business and aim to be a preferred partner for innovator pharma companies, instigating a paradigm shift in the life cycle management of iconic medicines. We seek to extensively engage with clinical communities to communicate product improvements and prioritise environmental, social, and governance considerations across the business and workforce.

Pharmanovia’s therapeutic areas include Cardiovascular, Oncology, Endocrinology and Neurology. www.pharmanovi.com